Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

VEERHEALTH CARE LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹49.45
at close · 8 Oct 2026
▼ 0.50 (-1.00%)

Latest filings

  1. Routine compliance filing for share dematerialization for Jul-Sep 2026 quarter · Compliance
  2. Veerhealth Care wins Rs 4.55 Cr skincare order from top FMCG company · Business Updates
  3. Trading window closed for insiders · Compliance
All filings ↓
Ask Nexa about VEERHEALTH CARE LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures and supplies personal care, skin care, hair care, oral care and body care products on a contract manufacturing basis for leading Indian FMCG companies, large Indian pharmacy and healthcare chains, and overseas buyers. The core business is making face care, skin care and personal care items for a 125-year-old Indian FMCG group under repeat orders (Rs. 3.60 crore in June 2026, Rs. 2.45 crore in May 2026, Rs. 76.40 lakhs sample order in July 2026), along with haircare and oral care products for a leading Indian pharmacy network (Rs. 1.11 crore order in July 2026). Exports form a growing line, with body care products shipped to a New York-based e-commerce platform (Rs. 1.43 crore order, April 2026) and a Rs. 15.73 lakh order for Gripe Water from a buyer in Sudan, the company's first order from that market. FY26 revenue from operations was Rs. 32.48 crore, up from Rs. 24.15 crore in FY25, with net profit of Rs. 0.54 crore. The company also markets its own AyuVeer brand, listed on Myntra, and received USFDA plant clearance in June 2025 to enable OTC drug product exports. A Veer Plast division has been added for backward integration. Management has guided FY27 income of around Rs. 105 crore with PAT of Rs. 5–6 crore, and FY28 income of around Rs. 156 crore with PAT of Rs. 9–10 crore.

Operating scale
FY26 revenue from operations
Rs. 32.48 croreFY26
FY25 revenue from operations
Rs. 24.15 croreFY25
FY26 net profit
Rs. 0.54 croreFY26
USFDA plant clearance
Received June 2025 for OTC drug product exports
Recent FMCG order (face care/skin care)
Rs. 3.60 crore, June 2026
Recent US e-commerce export order (body care)
Rs. 1.43 crore (~USD 151,200), April 2026
Who pays it
Indian FMCG companies (personal and household care), large Indian pharmacy and healthcare networks, US-based e-commerce platforms, and overseas buyers (Sudan).
Biggest cost
Other operating expenses at 12.8% of revenue is the largest disclosed cost line, followed by employee costs at 5.3% of revenue (FY26).
Kind of business
Small-cap contract manufacturer in personal care and OTC products, order-driven with a 45-day execution window, scaling into exports under a USFDA-cleared plant.
Where it sits
A BSE-listed small-cap pharmaceutical and personal care manufacturer with USFDA plant clearance, supplying on contract to leading Indian FMCG and pharmacy chains and to overseas buyers including a New York-based e-commerce platform.
Market Cap
₹99 Cr
P / E (TTM)
78.5×
EV / EBITDA
34.9×
Div Yield
—
Growth
25.2%▲
Revenue 5y CAGR
PAT +7.5% · EBITDA +18.5%
Quality
4.6%·
ROCE (5y median)
ROE 1.9% (5y median) · margin 9.1%
Leverage
0.20·
Debt / Equity · low
Net debt ₹4.12 Cr
Revenue FY21→FY26
3.1×▲
Margin −1.9 pts
₹11 Cr → ₹32 Cr
Cash conversion
2.76×▲
Operating cash ÷ profit · 5 yrs
₹8 Cr on ₹3 Cr
Moves on a normal day
0.77%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#134/158
P/B#106/163
ROCE#133/183
ROE#131/166
Debt / Equity#95/166
EBITDA margin#144/165
Revenue growth#5/161
Profit growth#151/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 25% a year over 5 years
Over 5 years it reported ₹2.83 Cr of profit and ₹7.80 Cr of operating cash — 2.76×
Profit is converting into cash
Concerns
Erratic profits — up in only 2 of the last 5 years
Returns on capital 4.6% (5-year median)
#133 of 183 in Pharmaceuticals on the latest reported figures
Customers are taking longer to pay — 53 → 109 days of receivables
FY21 → FY26
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from VEERHEALTH CARE LIMITED's filed financials and exchange disclosures

What does VEERHEALTH CARE LIMITED do?

VEERHEALTH CARE LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

Is VEERHEALTH CARE LIMITED profitable?

Yes. Over the trailing twelve months VEERHEALTH CARE LIMITED reported a net profit of ₹0.54 Cr on revenue of ₹32 Cr.

Does VEERHEALTH CARE LIMITED pay a dividend?

Not in the latest reported year — VEERHEALTH CARE LIMITED's dividend payout for FY26 was nil.

Is VEERHEALTH CARE LIMITED debt-free?

No. It reported borrowings of ₹4.58 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹4.12 Cr after cash. Debt stands at 0.20× equity. That is higher than 57% of its 166 Pharmaceuticals peers.

Is VEERHEALTH CARE LIMITED expensive compared with its peers?

On trailing P/E, VEERHEALTH CARE LIMITED ranks 134 of 158 in Pharmaceuticals — cheaper than 15% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.

How much does the VEERHEALTH CARE LIMITED share price move in a day?

On a typical session VEERHEALTH CARE LIMITED moves 0.77% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track VEERHEALTH CARE LIMITED's announcements?

Every NSE and BSE filing by VEERHEALTH CARE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.